These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17405756)

  • 1. Cocaine abuse may influence the response to imatinib in CML patients.
    Breccia M; Gentilini F; Alimena G
    Haematologica; 2007 Mar; 92(3):e41-2. PubMed ID: 17405756
    [No Abstract]   [Full Text] [Related]  

  • 2. [Survival following liver transplant due to imatinib-induced acute liver failure: a case study].
    García-Valdés M; Miras López M; Garrido Corro B; De La Rubia Nieto A
    Farm Hosp; 2012; 36(1):50-1. PubMed ID: 21514865
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 4. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib-induced immune hepatitis: case report and literature review.
    Al Sobhi E; Zahrani Z; Zevallos E; Zuraiki A
    Hematology; 2007 Feb; 12(1):49-53. PubMed ID: 17364993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.
    Bilgi N; Bell K; Ananthakrishnan AN; Atallah E
    Ann Pharmacother; 2010 May; 44(5):926-8. PubMed ID: 20332334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
    Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib: a review of its use in chronic myeloid leukaemia.
    Moen MD; McKeage K; Plosker GL; Siddiqui MA
    Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
    Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract]   [Full Text] [Related]  

  • 13. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
    Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
    Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
    [No Abstract]   [Full Text] [Related]  

  • 15. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 16. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
    Ostro D; Lipton J
    Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.
    Park SJ; Choi IK; Seo HY; Sung HJ; Park KH; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Acta Haematol; 2007; 118(4):219-21. PubMed ID: 18057867
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
    Govind Babu K; Attili VS; Bapsy PP; Anupama G
    Int Ophthalmol; 2007 Feb; 27(1):43-4. PubMed ID: 17410337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
    Prabhash K; Biswas G; Prasad N; Karant N; Sastry PS; Parikh PM
    Indian J Dermatol Venereol Leprol; 2006; 72(1):63-4. PubMed ID: 16481719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.